Skip to content

Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)

Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01499927
Acronym
AIR
Enrollment
74766
Registered
2011-12-26
Start date
2012-01-31
Completion date
2012-12-31
Last updated
2013-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection as Complication of Medical Care

Keywords

Early reassessment of intravenous antiinfective therapy

Brief summary

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Detailed description

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.

Interventions

Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* all in-patients in treatment with an intravenous antiinfective for \>60h, * hospitalized in a ward with computerized physician order entry (cpoe)

Exclusion criteria

* outpatients, * ward without cpoe, * no intravenous antiinfective treatment

Design outcomes

Primary

MeasureTime frame
duration of intravenous antiinfective therapy until switching1 year

Secondary

MeasureTime frame
costs (per year, per day and patient)1 year
defined daily doses (per 100 days)1 year
duration of hospitalization1 year
ratio of narrow to broad-spectrum antibiotics1 year
requests for consultations1 year

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026